Evidence map›Paper›PMID 39468387›Full record

ArticleJournal of cellular and molecular medicine2024

Immortalized mesenchymal stromal cells overexpressing alpha-1 antitrypsin protect acinar cells from apoptotic and ferroptotic cell death.

Sara Shoeibi, Erica Green, Hua Wei, Wenyu Gou, Charlie Strange, Hongjun Wang

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. AAT-MSC-EVs: Novel implications for suppressing ferroptosis, fibrosis and pain associated with chronic pancreatitis.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Sara ShoeibiDepartment of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Erica GreenDepartment of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Hua WeiDepartment of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Wenyu GouDepartment of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Charlie StrangeDepartment of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Hongjun WangDepartment of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.ORCID 0000-0001-7421-1917

Funding

Cellular Therapy for Type 1 Diabetes using Mesenchymal Stem CellsR01DK118529 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WANG, HONGJUN · 2019 to 2025
$3.8M
Autologous BM-MSCs and Islet Co-transplantation to Enhance Islet Survival and Function in TP-IAT PatientsR01DK126454 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WANG, HONGJUN · 2021 to 2025
$3.2M
Novel Gene and Stem Cell Therapy for Type 1 DiabetesR01DK120394 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WANG, HONGJUN · 2018 to 2021
$2.2M
Alpha1 Anti-trypsin Enhances Islet Autograft SurvivalR01DK105183 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WANG, HONGJUN · 2016 to 2020
$2.0M
Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of Chronic Pancreatitis and Its Associated PainUG3DK136705 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WANG, HONGJUN · 2023 to 2023
$328k
hAAT-engineered Mesenchymal Stem Cells for the Treatment of Chronic PainI01BX004536 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI Hongjun Wang · 2020 to 2026
–
BLRD VA I01 BX004536NIDDK NIH HHS R01 DK105183NIDDK NIH HHS R01DK105183NIDDK NIH HHS R01 DK118529NIDDK NIH HHS R01DK118529NIDDK NIH HHS R01 DK120394NIDDK NIH HHS R01DK120394NIDDK NIH HHS R01DK125454NIDDK NIH HHS R01 DK126454NIDDK NIH HHS UG3 DK136705NIDDK NIH HHS UG3DK136705VA VA-ORD BLR&D Merit I01BX004536)
6 · The paper itself

Abstract

Chronic pancreatitis (CP) is a progressive inflammatory disorder that impairs endocrine and exocrine function. Our previous work showed that mesenchymal stem/stromal cells (MSCs) and MSCs overexpressing alpha-1 antitrypsin (AAT-MSCs) could be therapeutic tools for CP. However, primary MSCs are predisposed to undergo senescence during culture expansion, which limits their therapeutic applications. We generated and characterized immortalized human MSCs (iMSCs) and AAT-MSCs (iAAT-MSCs) and tested their protective effect on 2,4,6-Trinitrobenzenesulfonic acid (TNBS)-induced acinar cell death in an in vitro cell culture system. Primary MSCs were immortalized by transduction with simian virus 40 large T antigen (SV40LT), and the resulting iMSC and iAAT-MSC lines were analysed for proliferation, senescence, phenotype and multi-differentiation potential. Subsequently, apoptosis and ferroptosis pathways were investigated by assessing changes before and after TNBS treatment. Coculture of iMSCs and iAAT-MSCs with acinar cell lines inhibited early cell death induced by TNBS, reduced ER stress and reversed TNBS-induced protein reduction at tight junctions. Additionally, iMSCs and iAAT-MSCs exerted such protection by regulating mitochondrial respiration, ATP content and ROS production in TNBS-induced acinar cells. Furthermore, iMSCs and iAAT-MSCs ameliorated TNBS-induced ferroptosis by modulating iron generation and ROS production and regulating the ferritin heavy chain 1 (FTH1)/protein disulfide isomerase (PDI)/glutathione peroxide 4 (GPX4) signalling pathways in acinar cells. These findings identify ferroptosis as an unrecognized mechanism that leads to TNBS-induced cell death and offer mechanistic insights relevant to using stem cell therapy to treat acinar cell death associated with CP.

Indexed as

Acinar Cellsalpha 1-AntitrypsinApoptosisFerroptosisMesenchymal Stem CellsCell DifferentiationCell ProliferationEndoplasmic Reticulum StressHumansTrinitrobenzenesulfonic Acidalpha 1-AntitrypsinTrinitrobenzenesulfonic Acidacinar cell deathchronic pancreatitisferroptosisimmortalized human MSCs

Identifiers

PMID39468387
PMCPMC11518823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.